Back to top
more

BioRad Laboratories (BIO)

(Delayed Data from NYSE)

$276.80 USD

276.80
530,933

-7.80 (-2.74%)

Updated Aug 4, 2025 04:00 PM ET

After-Market: $276.78 -0.02 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 30% (173 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Headquartered in Hercules, CA, Bio-Rad Laboratories is a manufacturer and global supplier of clinical diagnostics and life science research products in the healthcare, analytical chemistry life science research and other markets. It offers a wide portfolio of products and systems which allow the separation of complex chemical and biological materials and discovery, analysis and purification of their components. Bio-Rad has extensive and direct distribution channels in over 35 countries outside the United States through subsidiaries which focus on sales, customer service and product distribution.

Zacks Equity Research

UnitedHealth (UNH) to Post Q1 Earnings: What You Should Expect

by Zacks Equity Research

UnitedHealth's (UNH) first-quarter results are likely to reflect growing premiums and memberships.

John Blank headshot

The Bears Short Real Estate Stocks: Zacks April Strategy

by John Blank

Bulls say "buy when there is blood on the streets" -- meaning buy now. The bear response is "there will another shoe to drop" -- meaning stay away.

Zacks Equity Research

Here's Why You Should Retain Molina (MOH) in Your Portfolio

by Zacks Equity Research

Molina's (MOH) inorganic growth activities, financial flexibility and cost-cutting initiatives poise it well for growth.

Zacks Equity Research

Community Health (CYH) Divests Hospital for $92 Million

by Zacks Equity Research

Community Health (CYH) divests a healthcare facility in West Virginia, thereby reinforcing the sincere focus that it puts to shed non-core assets and use funds to grow well-performing business areas.

Zacks Equity Research

Verano Holdings Corp. (VRNOF) Q4 Earnings Surpass Estimates

by Zacks Equity Research

Verano Holdings Corp. (VRNOF) delivered earnings and revenue surprises of 300% and 0.77%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Select Medical's (SEM) Orlando Facility to Boost Post-Acute Care

by Zacks Equity Research

Select Medical (SEM) aims to address the post-acute care demand in the Central Florida region through the construction of a specialty hospital in Orlando.

Zacks Equity Research

SurModics (SRDX) Moves 5.4% Higher: Will This Strength Last?

by Zacks Equity Research

SurModics (SRDX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Zacks Equity Research

Here's Why You Should Retain Acadia (ACHC) in Your Portfolio

by Zacks Equity Research

Diversified revenue base, improving top line, strategic expansion initiatives and joint ventures poise Acadia Healthcare (ACHC) well for growth.

Zacks Equity Research

Wall Street Analysts Predict a 28.56% Upside in Bio-Rad (BIO): Here's What You Should Know

by Zacks Equity Research

The mean of analysts' price targets for Bio-Rad (BIO) points to a 28.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks Equity Research

Is BridgeBio Pharma (BBIO) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how BridgeBio Pharma (BBIO) and Bio-Rad Laboratories (BIO) have performed compared to their sector so far this year.

Zacks Equity Research

Here's Why You Should Retain Bio-Rad (BIO) Stock for Now

by Zacks Equity Research

Investors are optimistic about Bio-Rad (BIO), owing to robust demand in Life Science and Clinical Diagnostics arms.

Zacks Equity Research

Bio-Rad (BIO) Global Expansion Strong, FX Woe Dents Growth

by Zacks Equity Research

Bio-Rad (BIO) experiences double-digit currency-neutral core revenue growth in the Americas and Asia in Q4.

Zacks Equity Research

BD (BDX) Boosts Molecular Diagnostics Portfolio With New Tests

by Zacks Equity Research

Recent developments in the Molecular Diagnostics space have been aiding key MedTech players like BD (BDX) to boost their business.

Zacks Equity Research

Bio-Rad (BIO) Q4 Earnings Miss Estimates, Operating Margin Up

by Zacks Equity Research

Excluding COVID-related sales, Life Science revenues at Bio-Rad (BIO) increase 28.1%, primarily driven by Droplet Digital PCR, process chromatography, Western blotting and qPCR products.

Zacks Equity Research

Bio-Rad Laboratories (BIO) Misses Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Bio-Rad (BIO) delivered earnings and revenue surprises of -4.06% and 2.93%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

VAREX IMAGING (VREX) Misses Q1 Earnings Estimates

by Zacks Equity Research

VAREX IMAGING (VREX) delivered earnings and revenue surprises of -27.27% and 0.12%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Bio-Rad (BIO) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Sustained sales gains in terms of the Bio-Rads (BIO) process media, western blotting, Droplet Digital PCR and qPCR products are likely to drive Q4 revenues.

Zacks Equity Research

Here's Why You Should Retain Bio-Rad (BIO) Stock for Now

by Zacks Equity Research

Investors are optimistic about Bio-Rad (BIO), led by robust demand in the Life Science and Clinical Diagnostics arms.

Zacks Equity Research

Bio-Rad (BIO) Core Diagnostic Sales Grow Amid Supply Challenges

by Zacks Equity Research

Bio-Rad's (BIO) underlying Life Science currency-neutral core revenue growth is primarily driven by Western loading, qPCR, process media and antibody products sales.

Zacks Equity Research

Bio-Rad (BIO) Q3 Earnings Surpass Estimates, Margins Down

by Zacks Equity Research

Bio-Rad's (BIO) third-quarter revenues decline mainly as a result of lower COVID-related sales compared with the year-ago period.

Zacks Equity Research

Bio-Rad Laboratories (BIO) Surpasses Q3 Earnings Estimates

by Zacks Equity Research

Bio-Rad (BIO) delivered earnings and revenue surprises of 0.39% and 1.34%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Indrajit Bandyopadhyay headshot

Medical Device Stocks' Q3 Earnings on Oct 27: LH, BIO & More

by Indrajit Bandyopadhyay

Medical Device players are likely to have benefited from the reopening of economies and several efforts to combat staffing challenges. Let's see how LH, BIO, BAX, DXCM and WST are likely to fare this time.

Zacks Equity Research

Bio-Rad (BIO) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Owing to the impact of the Russia-Ukraine war situation, supply chain constraints, as well as the inflationary situation, we expect Bio-Rad's (BIO) Life Science arm to experience a year-over-year decline.

Zacks Equity Research

Walgreens (WBA) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Walgreens (WBA) is expected to have registered growth in Q4 in its U.S. retail pharmacy business, banking on demand for vaccinations and tests amid the ongoing series of contagious virus spread.

Zacks Equity Research

Reasons to Retain Veeva Systems (VEEV) Stock in Your Portfolio

by Zacks Equity Research

Veeva Systems' (VEEV) slew of strategic deals raises optimism about the stock.